Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

Sima Jeha(St. Jude Children's Research Hospital), C‐H Pui(St. Jude Children's Research Hospital), David Irwin(Alta Bates Summit Medical Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Bruce M. Camitta(Medical College of Wisconsin), S. Shenoy(Washington University in St. Louis), Violet Shen(Children's Hospital of Orange County), Susan M. Blaney(Pediatrics and Genetics)
Leukemia
October 28, 2004
10.1038/sj.leu.2403566
Cited by 180

Related Papers

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
|Blood|2006|475
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
|Blood|1989|456
Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge
|Journal of Clinical Oncology|2015|450
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
|Leukemia|2012|440